SCHEMBL4041382

SCHEMBL4041382

Cn1c(SCCCN)nnc1-c1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 8/20 0.71
DRD3 P35462 8/20 0.66
NPC1 O15118 3/20 0.59
RAB9A P51151 2/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2C19 P33261 1/20 0.59
HTT P42858 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.56
HTR1A P08908 1/20 0.55
ADRA2A P08913 1/20 0.55
ADRA2B P18089 1/20 0.55
ADRA2C P18825 1/20 0.55
DRD4 P21917 1/20 0.55
DRD5 P21918 1/20 0.55
HRH2 P25021 1/20 0.55
HTR1B P28222 1/20 0.55
HTR2A P28223 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4045328 0.92 DRD2 (0.61) DRD2DRD3NPC1RAB9AMEN1
SCHEMBL4385569 0.85 DRD2 (0.71) DRD2DRD3NPC1RAB9AMEN1
SCHEMBL11512132 0.84 DRD2 (0.78) DRD2DRD3NPC1RAB9AMEN1
SCHEMBL4705828 0.82 DRD2 (0.66) DRD2DRD3NPC1RAB9AMEN1
SCHEMBL4702745 0.80 DRD2 (0.63) DRD2DRD3NPC1RAB9AMEN1
SCHEMBL9224636 0.80 DRD2 (0.77) DRD2DRD3NPC1RAB9AMEN1
SCHEMBL4197148 0.77 NPC1 (0.81) DRD2NPC1RAB9AMEN1KMT2A
SCHEMBL4206819 0.75 NPC1 (0.66) DRD2DRD3NPC1RAB9AMEN1
SCHEMBL4389064 0.75 DRD3 (0.69) DRD2DRD3HTR1AADRA2AADRA2B
SCHEMBL4051149 0.75 DRD2 (0.60) DRD2DRD3NPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140908-B1 TRIAZOLE COMPOUNDS WITH DOPAMINE-D3-RECEPTOR AFFINITY ABBOTT GMBH & CO KG (DE) 2009-03-04 EP disclosed
EP-1140907-B1 TRIAZOLE COMPOUNDS WITH DOPAMINE-D3-RECEPTOR AFFINITY ABBOTT GMBH & CO KG (DE) 2007-07-11 EP disclosed
US-6583166-B1 Fewer side effects than D2 receptor antagonist neuroleptics; cardiovascular, kidney, central nervous system disorders; 3-(3-((4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)sulfanyl) propyl)-1,3,3a,4,5,9b-hexahydro-2H-benzo(e)indol-2-one ABBOTT LABORATORIES 2003-06-24 US disclosed
US-6579892-B1 Affective disorders; neurotic, stress and somatoform disorders and psychoses, e.g. schizophrenia 3-(3-(6-Methyl-1,2,3,4-tetrahydronaphth-2-ylamino)propylmercap to) -4-methyl-5-phenyl-1,2,4(4H)-triazole ABBOTT LABORATORIES 2003-06-17 US disclosed
EP-1140908-A1 TRIAZOLE COMPOUNDS WITH DOPAMINE-D3-RECEPTOR AFFINITY BASF AKTIENGESELLSCHAFT (DE) 2001-10-10 EP disclosed
WO-2000042038-A1 TRIAZOLE COMPOUNDS WITH DOPAMINE-D3-RECEPTOR AFFINITY BASF AKTIENGESELLSCHAFT (DE) 2000-07-20 WO disclosed